REJECTION MECHANISM AND IMMUNOSUPPRESSIVE STRATEGY OF SMALL BOWEL TRANSPLANTATION.

小肠移植的排斥机制和免疫抑制策略。

基本信息

  • 批准号:
    09671835
  • 负责人:
  • 金额:
    $ 1.6万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1999
  • 项目状态:
    已结题

项目摘要

The p38 mitogen-activated protein kinase (MAPK) is a stress-activated enzyme responsible for transducing inflammatory signals. On CD8+ T lymphocytes, p38 expression correlates with cytotoxic activity. Concerning apoptotic signaling pathways, p38 is activated by TNF-α and activation of p38 may induce apoptosis. Methods. Heterotopic small bowel transplantation (SBT) was performed. Group1. LEW → LEW (n=3), Group2. BN → LEW (n=5, no treatment), Group3, BN → LEW (n=3, FK506 0.5 mg/kg, i.m.for 7 days). Group4 BN → LEW (n=3, anti-TNF-α antibody ; 1.0mg/kg, i.p.injection at SBT). Histology, apoptosis, immunostaining of p38 and phosphospecific p38, and Western blot of phosphospecific p38 were examined. Results. The histopathologic findings of Group 1 on day 7 after transplantation, moderate to serve rejection was observed in Group 2. On the other hand, Group 3 and 4 on day 7 after transplantation showed mild to moderate rejection. The graft infiltrating CD8a/p38-double positive cells in Group 2 significantly increased compared with Group3. Concerning TUNEL-positive cells 10 HPF by Mann-Whitney U-test, there were more positive cells in Group 2 (9.4±3.6) than in Group 1 (0.7±0.6) (p=0.024). However, the number of positive cells in Group 4 (4.3±1.5) decreased significantly compared with Group 2 (p=0.047). There was no significant difference in the number of cells expressing p38 among four groups. In expression of phosphospecific p38, the numbers of positive cells in Group 2 seemed like more than that in Group 4. In the western blotting of phosphospecific p38 in rejecting allografts, immunoreactive bands in Group 2 were detected stronger than that in Group 4. Conclusions. Since the infiltrating cells at allograft rejection would predominantly express phosphospecific p38, combined FK506 and anti-TNF antibody therapy might success by suppressing the activation of p38.
p38有丝分裂原激活的蛋白激酶(MAPK)是导致炎症信号的AS-ACTIVAVAVE,P38表达与细胞毒性活性相关。进行异位小肠移植(SBT)。 ,抗TNF-α抗体;在p38和磷酸体p38的p38中,p38的p38染色。另一方面,移植后第3和4天的第7天显示了与第2组相比,第2组中的移植物浸润CD8A/P38双阳性细胞显着增加。惠特尼U检验,第2组(9.4±3.6)中有更多的阳性细胞(0.7±0.6)(p = 0.024)。在第4组中表达p38的细胞数量。主要表达磷酸p38 506和抗TNF抗体疗法可能通过抑制p38的激活而成功。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KANEHIRO Hiromichi其他文献

KANEHIRO Hiromichi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KANEHIRO Hiromichi', 18)}}的其他基金

New transplantation strategy of gut like organ differentiation from pluripotent stem cells by tissue engineering
通过组织工程从多能干细胞分化肠样器官的新移植策略
  • 批准号:
    24592699
  • 财政年份:
    2012
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New treatment strategy for Hirschsprung's disease with neural crest stem cells by tissue-engneering
组织工程神经嵴干细胞治疗先天性巨结肠症的新策略
  • 批准号:
    21592280
  • 财政年份:
    2009
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Mechanism of graft injury and regeneration in small bowel transplantation
小肠移植损伤与再生机制
  • 批准号:
    19592065
  • 财政年份:
    2007
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
THERAPEUTIC POTENTIAL OF TARGETING ANIGIOGENESIS IN CHRONIC REJECTION AND ISCHEMIA-REPERFUSION INJURY IN SMALL BOWEL TRANSPLANTATION
小肠移植中慢性排斥和缺血再灌注损伤中靶向血管生成的治疗潜力
  • 批准号:
    17591867
  • 财政年份:
    2005
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ROLE OF ANGIOGENESIS AND POTENTIAL OF ANTIANGIOGENESIS AS POSTTRANPLANT TREATMENT IN SMALL BOWEL TRANSPLANTATION
血管生成的作用以及抗血管生成作为小肠移植术后治疗的潜力
  • 批准号:
    15591891
  • 财政年份:
    2003
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
TORELANCE INDUCTION AND IMMUNOSUPPRESSIVE STERATEGY OF SMALL BOWEL TRANSPLANTATION.
小肠移植的 TOrelance 诱导和免疫抑制策略。
  • 批准号:
    12671741
  • 财政年份:
    2000
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
MECHANISM OF TRANSPLANT CHIMERISM AND SIGNIFICANCE OF MIGRATION OF DONOR-DERIVED CELLS IN ORGAN
移植嵌合机制及供体来源细胞在器官中迁移的意义
  • 批准号:
    05671020
  • 财政年份:
    1993
  • 资助金额:
    $ 1.6万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

EGF Receptor Endocytosis: Mechanisms and Role in Signaling
EGF 受体内吞作用:机制及其在信号传导中的作用
  • 批准号:
    10552100
  • 财政年份:
    2023
  • 资助金额:
    $ 1.6万
  • 项目类别:
The roles of AP-1 pathway activation in NK cell development and exhaustion programming in AML
AP-1 通路激活在 NK 细胞发育和 AML 衰竭编程中的作用
  • 批准号:
    10751755
  • 财政年份:
    2023
  • 资助金额:
    $ 1.6万
  • 项目类别:
VRC Inhibiting p38 to Prevent and Restore Corneal Scarring
VRC 抑制 p38 以预防和恢复角膜疤痕
  • 批准号:
    10833743
  • 财政年份:
    2023
  • 资助金额:
    $ 1.6万
  • 项目类别:
Role of Interferon-Gamma / Interleukin-12 Axis in Metabolic Liver Disease
干扰素-γ/白介素-12 轴在代谢性肝病中的作用
  • 批准号:
    10735419
  • 财政年份:
    2023
  • 资助金额:
    $ 1.6万
  • 项目类别:
Targeting SHP-1 through a newfound metabolite-regulated cysteine activation site
通过新发现的代谢物调节的半胱氨酸激活位点靶向 SHP-1
  • 批准号:
    10802649
  • 财政年份:
    2023
  • 资助金额:
    $ 1.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了